Lucassen A M, de Waal R M, Verheugt F W
Hartcentrum, Academisch Ziekenhuis St. Radboud, Nijmegen.
Ned Tijdschr Geneeskd. 2000 Apr 1;144(14):650-5.
Currently, our treatment modalities for patients with severe coronary artery disease consist of combinations of medication, percutaneous transluminal coronary angioplasty (PTCA) and coronary revascularization operations. Still, the number of patients who cannot be treated adequately in these ways is growing. In recent years progress has been made in the field of angiogenesis: the process of the development of new capillaries. It is now known that blood vessel growth is an essential phenomenon in a range of disease. It is possible to inhibit or stimulate this process, offering hope for new treatments in a wide array of diseases. Stimulation of angiogenesis has already been successful in animal models of chronic peripheral and myocardial ischaemia. Results of experimental treatments of coronary patients have been reported since 1998. 'Therapeutic angiogenesis' may evolve as our fourth treatment modality for the treatment of coronary artery insufficiency.
目前，我们对重症冠状动脉疾病患者的治疗方式包括药物治疗、经皮腔内冠状动脉成形术（PTCA）和冠状动脉血运重建手术的联合应用。然而，无法通过这些方法得到充分治疗的患者数量仍在增加。近年来，血管生成领域取得了进展：即新毛细血管形成的过程。现在已知血管生长是一系列疾病中的一种重要现象。抑制或刺激这一过程是可能的，这为多种疾病的新治疗方法带来了希望。血管生成的刺激在慢性外周和心肌缺血的动物模型中已取得成功。自1998年以来已有冠状动脉患者实验性治疗的结果报道。“治疗性血管生成”可能会发展成为我们治疗冠状动脉供血不足的第四种治疗方式。
